1. Introduction {#sec1}
===============

Morphine is the current first-line recommended medication for pain management in patients with acute coronary syndrome (ACS) (Level of Evidence B, ACC/AHA guidelines).[@bib1], [@bib2], [@bib3] Fentanyl is also widely used for moderate sedation during percutaneous coronary intervention (PCI). The goal is to reduce pain, suffering, anxiety, and dyspnea.[@bib2], [@bib3], [@bib4] Pain relief could help ease the sympathetic drive.[@bib5] A concern has been raised that narcotic co-administration with P2Y12 inhibitors may reduce the levels of these orally administered antiplatelet agents through gastrointestinal transit delay.[@bib6] This is especially important in the immediate post-PCI period when the thrombogenic potential is the highest. The updated 2017 European Society of Cardiology guidelines on acute myocardial infarction (AMI) management has highlighted these concerns.[@bib6] With the widespread use of newer P2Y12 inhibitors, there is a need to assess the safety of concurrent pain management with morphine during AMI, given the above interaction. Several studies have investigated the effects of concurrent use of morphine and P2Y12 inhibitors on adverse cardiovascular outcomes in patients with AMI; however, there is lack of clarity on the judicious use of morphine in this patient population.

2. Methods {#sec2}
==========

2.1. Data source and search strategy {#sec2.1}
------------------------------------

The systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.[@bib7] We searched PubMed, EMBASE, Cochrane Central, [clinicaltrials.gov](http://clinicaltrials.gov){#intref0010} databases, without any language restrictions, from inception to April 2018. An experienced medical reference librarian assisted in the search. Two authors (GV, AK) independently reviewed each article for eligibility for inclusion. The two above authors independently extracted data from the included studies, including demographic, laboratory, and outcome data. Any disagreements were solved through consensus and/or by the third reviewer (SG).

The following keywords were used for search in various combinations: morphine, fentanyl, opioid, prasugrel, ticagrelor, clopidogrel, platelet function test, myocardial infarction, myocardial ischemia, and ACS. National and international conferences proceedings were searched for related abstract publications. Search terms were devised using wildcards to account for variations in spellings. Retrieved articles were then screened for any mention of opioid use to identify pertinent articles. References in review articles were screened manually for potential appropriate articles. The criteria for inclusion included: prospective studies of platelet function (randomized, observational, or sub-studies), and documentation of narcotic use for the purpose of pain relief in AMI prior to loading dose of antiplatelet agents.

2.2. Data extraction {#sec2.2}
--------------------

Morphine use was defined as morphine administration prior to the initial oral P2Y12 loading during PCI. However, the criteria for morphine use was not standardized to a particular dose or timing. The remaining patients without documented morphine use, as defined above, were counted under no-morphine category. Patient demographic data, past medical history, medication use, and outcome data were noted if provided in the studies. Platelet function was assessed using platelet function tests. In specific, three different tests are available for platelet function---VerifyNow test measures platelet reactive units (PRU), vasodilator-associated stimulated phosphoprotein (VASP) assay measures platelet reactivity index (PRI), and various forms of platelet aggregometry--electrical impedance, light, and chemical measured in Units (U)---measure platelet aggregation. VerifyNow is performed at the point-of-care and uses photometric assessment of platelet aggregation. VASP is a laboratory test involving flow-cytometric analysis of platelet vasodilator-stimulated phosphoprotein phosphorylation while platelet aggregometry involves adenosine diphosphate (ADP)-induced platelet aggregation and assessment of light or electrical transmission/impedance. Higher values in all these tests suggest higher platelet reactivity. In the context of AMI, they are used to assess patient\'s platelet reactivity to antiplatelet medications including P2Y12 inhibitors. The cut-off for high residual platelet reactivity (HRPR) was defined as per choice of platelet function test---PRU \>208, PRI \>50%, and aggregometry \>46 U, respectively.

Pharmacokinetic data were only available for ticagrelor in the form of maximum ticagrelor concentration (*C*~max~). Graph of plasma concentration to time was reported as area under curve (AUC); however, the period of assessment varied from 12 h after the loading dose (AUC~0-12~)[@bib8] to the time for last measurable concentration (AUC~0-t~).[@bib9] Metabolite assessment (AR-C124910XX) was excluded from the assessment.

2.3. Bias assessment {#sec2.3}
--------------------

Risk of bias was assessed using Risk of Bias in Nonrandomized Studies of Interventions tool[@bib10] for nonrandomized study data. Studies were evaluated on the following domains: confounding bias, selection bias, classification of intervention bias, deviation from intended intervention bias, missing data bias, outcome measurement bias, and selective reporting bias. For the randomized trials, the Cochrane risk of bias tool was used.[@bib11] This tool was used to assess the domains of adequacy of random sequence generation, allocation concealment, blinding of participants and physicians, blinding of outcome assessment, selective reporting, and other potential bias. Each domain was then scored as low, moderate, serious, or critical risk of bias.

2.4. Statistical analysis {#sec2.4}
-------------------------

Continuous data were extracted as mean or median. Median with interquartile range was converted to mean and standard deviation.[@bib11] For continuous variables including Cmax and AUC, the mean difference (MD) was calculated between morphine and non-morphine groups (fixed-effects model). Standardized mean difference (SMD) was calculated for platelet function assessed by the various assays, at 2 h time-point after the loading dose of anti-platelet agent (random-effects model). The presence of HRPR, as defined above, after 2 h of oral P2Y12 inhibitor loading was counted as events. To account for the variability in study design, result reporting, and outcome assessment, only data measured at the same time-point following the oral P2Y12 inhibitor loading were used for quantitative analysis. When more than one platelet function test were used in the same study, the test with the most number of patient data was used.

Clinical outcomes included in-hospital mortality, stroke, and re-infarction/stent thrombosis in both groups. These outcomes were combined together into a composite endpoint-major adverse cardiovascular events (MACE), because none of the studies were powered to assess each outcome independently. Meta-analysis was performed using a fixed-effects model when heterogeneity was not significant and with random model if heterogeneity was significant. Odds ratio (OR) was calculated from the analyses. Review Manager v5.2 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014) was used for all statistical analyses. The fixed-effects model was used for all analyses except platelet function assays where the random-effect model was used. Heterogeneity was assessed using I^2^ statistic.[@bib12] Publication bias was estimated using the funnel plot.[@bib11] Finally, to assess the validity of the results from observational studies, a sensitivity analysis was performed by excluding the randomized controlled trial (RCT) from the analysis.

3. Results {#sec3}
==========

Literature search identified 72 individual studies of which 8 studies were eligible for analysis with a total 752 AMI patients[@bib3], [@bib8], [@bib9], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17] ([Fig. 1](#fig1){ref-type="fig"}). An attempt was also made to gather the non-reported data by contacting the corresponding authors via email. No response was obtained.Fig. 1Flowsheet for inclusion into the analysis (PRISMA flowsheet). AMI, acute myocardial infarction; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.Fig. 1

[Table 1](#tbl1){ref-type="table"} summarizes the characteristics of studies including the study design, whereas [Table 2](#tbl2){ref-type="table"} has the baseline characteristics regarding patients included in the individual studies when available. Studies were excluded if performed on healthy subjects,[@bib18], [@bib19] incomplete data,[@bib9], [@bib16] or not exclusively enrolling AMI patients.[@bib20], [@bib21] The eligible studies included one RCT,[@bib8] three prospective observational studies,[@bib13], [@bib14], [@bib15] three post-hoc analyses of individual RCTs,[@bib9], [@bib16], [@bib17] and one integrative analysis of five prospective observational studies performed by a single group.[@bib3] One study[@bib15] used abciximab as a bridge to counteract the effects of morphine on P2Y12 inhibitor absorption; only the data from those patients who did not receive abciximab were used for our analysis. Clopidogrel use was reported in one study,[@bib22] ticagrelor was the P2Y12 inhibitor used in three studies,[@bib8], [@bib9], [@bib16] and prasugrel was used in three studies,[@bib14], [@bib15], [@bib17] whereas two studies reported usage of both ticagrelor and prasugrel[@bib3], [@bib13] (ticagrelor = 493 patients, prasugrel = 259 patients). Morphine use was reported in 328 patients, and the remaining 424 patients were included in the non-morphine group. All studies included only patients who presented with ST-elevation myocardial infarction (STEMI) except one study[@bib8] which also included patients with non--ST-elevation myocardial infarction (NSTEMI). There was no difference in the risk factors (age, hypertension, and diabetes) between morphine and non-morphine groups ([Supplemental Fig. 1](#appsec1){ref-type="sec"}). There was also no difference in the rates of prior PCI and history of MI (data not shown).Table 1Description of studies included in analysis.Table 1StudyStudy typePopulationNumber of patientsAspirin doseP2Y12 inhibitor usedMedian narcotic dosePlatelet function assessmentHRPR cut-offBellandi et al.[@bib13]Prospective observationalSTEMI182 (morphine = 74, non-morphine = 108)300--500 mgTicagrelor 180 mg = 131 and prasugrel 60 mg = 51Morphine 6 ± 3 mgVerifyNowPRU ≥ 208Flierl et al.[@bib14]Prospective observationalSTEMI50 (morphine = 33, non-morphine = 15, unclear = 2)500 mgPrasugrel 60 mgMorphine (1--17.5 mg)VASPPRI \> 50%Franchi et al.[@bib9]Post-hoc of randomized trialSTEMI46 (morphine = 16, non-morphine = 30)325 mgTicagrelor (180 mg = 16, 270 mg = 15, 360 mg = 15)Morphine (dose unclear)VASP and VerifyNowPRI \> 50%, PRU \> 208Kubica et al.[@bib8]Single center, randomized, placebo controlledAcute MI (STEMI 45 and NSTEMI 29)74 (morphine = 37, non-morphine = 37)300 mgTicagrelor 180 mgMorphine 5 mgVASP, VerifyNow, Electrode aggregometryPRI \> 50%, PRU \> 208 and AUC \> 46 U respectivelyParodi et al.[@bib4]Integrative analysis of 5 independent studiesSTEMI300 (morphine = 95, non-morphine = 205)300--500 mgTicagrelor 180 mg = 205 and prasugrel 60 mg = 95Morphine 4 mg (2--6 mg)VerifyNowPRU ≥ 208Siller-Matula et al.[@bib15]Prospective observationalSTEMI32 (morphine = 19, non-morphine = 13)250 mgPrasugrel 60 mgVariable from 5 to 15 mg morphineImpedance aggregometryAUC \> 46 UnitsSilvain et al.[@bib16]Post-hoc of the randomized ATLANTIC trial[@bib23]STEMI37 (morphine = 22, non-morphine = 15)All patients received but doses not availableTicagrelor 180 mg (21 prehospital, 16 in-hospital)Morphine (dose unclear)VASP and VerifyNowPRI \> 50% or PRU \> 235Zeymer et al.[@bib17], [@bib24]Post-hoc of the randomized ETAMI trialSTEMI62 (morphine = 32, non-morphine = 30)500 mg iv or 300 mg oralClopidogrel 600 mg = 31 and 60 mg prasugrel = 31Morphine (dose unclear)VASPPRI \> 50%[^1]Table 2Baseline demographic data of the studies when available.Table 2StudyMorphine useNo. of patientsAgeMaleBMIHTNDMPrior MIPrior PCI/CABGCulprit vessel/location of infarctionParodi et al.[@bib4]Morphine9562.073%26.848%15%8%8%50% Anterior infarctionNon-morphine20561.179%28.154%11%7%6%42% Anterior infarctionBellandi et al.[@bib25]Morphine746473%2755%16%8%7%1% Left main, 45% LAD, 15% LCx, and 38% RCANon-morphine1086476%2760%23%8%9%3% Left main, 40% LAD, 18% LCx, and 36% RCAFlierl et al.[@bib14]Morphine335690%56%22%Non-morphine15Kubica et al.[@bib8]Morphine3560.766%27.643%23%14%11%Non-morphine3562.580%27.460%14%23%26%Siller-Matula et al.[@bib15]Morphine195894%56%17%22%18%Non-morphine136384%72%9%18%9%[^2]

The results of bias assessment are summarized in [Table 3](#tbl3){ref-type="table"}A and [Fig. 2](#fig2){ref-type="fig"}A for nonrandomized studies, and in [Table 3](#tbl4){ref-type="table"}B and [Fig. 2](#fig2){ref-type="fig"}B for the randomized study (RCT). The overall bias in the studies was found to be low; however, all the studies were limited by confounding.Table 3ARisk of bias in nonrandomized studies.Table 3AStudy type: nonrandomized studiesAuthorBias due to confoundingBias in selection of participants into studyBias in classification of interventionsBias due to deviations from intended interventionBias due to missing dataBias in measurement of outcomesBias in selection of the reported resultBellandi et al.[@bib13]SERIOUS\
Not adjusted for baseline pain scores and comorbidities.LOW\
Consecutive patientsSERIOUS\
Dose, timing, frequency, and setting of morphine use was not clearly defined or blindedLOW\
No deviations beyond usual careLOW\
All patients availableLOW\
Objective lab tests used for outcome assessmentLOW\
Required data reportedFlierl et al.[@bib14]SERIOUS\
Not adjusted for baseline pain scores, comorbidities.LOW\
Consecutive patientsSERIOUS\
Dose, timing, frequency, and setting of morphine use was not clearly defined.SERIOUS\
Metoclopramide co-intervention in some patientsLOW\
Two patients without morphine dataLOW\
Objective lab tests used for outcome assessmentMODERATE\
Some selective reporting of assessed resultsFranchi et al.[@bib9]SERIOUS\
Not adjusted for baseline pain scores and comorbidities.LOW\
Substudy of randomized studySERIOUS\
Dose, timing, frequency, and setting of morphine use was not clearly defined.SERIOUS\
Variable loading dose of ticagrelor (as per the actual design of trial)LOW\
All patients availableLOW\
Objective lab tests used for outcome assessmentLOW\
Required data reportedParodi et al.[@bib4]SERIOUS\
Not adjusted for baseline pain scores and comorbidities.MODERATE\
Unclear if consecutive patients usedSERIOUS\
Dose, timing, frequency, and setting of morphine use was not clearly defined.LOW\
No deviations beyond usual careLOW\
All patients availableLOW\
Objective lab tests used for outcome assessmentLOW\
Required data reportedSiller-Matula et al.[@bib15]SERIOUS\
Not adjusted for baseline pain scores and comorbidities.LOW\
Substudy of randomized studySERIOUS\
Dose, timing, frequency, and setting of morphine use was not clearly defined.LOW\
No deviations beyond usual care (patients who received abciximab were selectively excluded from the meta-analysis)LOW\
All patients availableLOW\
Objective lab tests used for outcome assessmentLOW\
Required data reportedSilvain et al.[@bib16]SERIOUS\
Not adjusted for baseline pain scores and comorbidities.LOW\
Substudy of randomized studySERIOUS\
Dose, timing, frequency, and setting of morphine use was not clearly defined.SERIOUS\
Prehospital and hospital administration of ticagrelor was not adjusted between groupsLOW\
All patients availableLOW\
Objective lab tests used for outcome assessmentSERIOUS\
Selective reporting of resultsZeymer et al.[@bib17], [@bib24]SERIOUS\
Not adjusted for baseline pain scores and comorbidities.LOW\
Substudy of randomized studySERIOUS\
Dose, timing, frequency, and setting of morphine use was not clearly defined.LOW\
No deviations beyond usual care (clopidogrel administered patients were selectively excluded from the meta-analysis)LOW\
All patients availableLOW\
Objective lab tests used for outcome assessmentLOW\
Required data reportedFig. 2A: Graphical representation of risk of bias in non-randomized study. B: Graphical representation of risk of bias in the randomized study. NRS, nonrandomized study; RCT, randomized controlled trial.Fig. 2Table 3BRisk of bias in the randomized study.Table 3BStudy type: randomized studyAuthorRandom sequence generation (selection bias)Allocation concealment (selection bias)Blinding of participants and personnel (performance bias)Blinding of outcome assessment (detection bias)Incomplete outcome data addressed (attrition bias)Selective reporting (reporting bias)Other biasKubica et al.[@bib8]LOW\
Random Allocation Software usedLOW\
Random Allocation Software usedLOW\
Blinded personnel (or investigators), unclear but presumed blinding of patientsLOW\
Objective lab tests used for outcome assessmentMODERATE\
One patient in each group without results. Results of all three platelet studies not available for all patientsLOW\
Required data reportedMODERATE\
Co-intervention with fentanyl for moderate sedation not reported. Alternate pain control strategy or crossover patients not reported.

3.1. Pharmacodynamic effect {#sec3.1}
---------------------------

Five studies[@bib3], [@bib8], [@bib13], [@bib15], [@bib17] reported the effect of morphine use on platelet function; two studies used the VerifyNow test,[@bib3], [@bib13] one used electrical impedance aggregometry,[@bib15] one used VASP test,[@bib17] and one used all three tests.[@bib8] Since the platelet function test used by different studies and their cut-offs for HRPR were not uniform, there was significant heterogeneity in reporting (I^2^ = 57%, *p* = 0.04). Morphine use was associated with higher platelet function at 2 h suggestive of decreased inhibition of the platelet pool as compared with non-morphine group (SMD = 0.77, 95% CI = 0.46--1.08, *p* \< 0.001) ([Fig. 3](#fig3){ref-type="fig"}A). Similarly, four studies[@bib3], [@bib8], [@bib14], [@bib15] reported the HRPR rates following P2Y12 inhibitor loading at 2 h. Morphine was associated with higher incidence of HRPR at 2 h with an odds ratio of 3.37 (95% CI 2.20--5.15, *p* \< 0.001). There was no significant heterogeneity in between the studies (I^2^ = 17%, *p* = 0.30) ([Fig. 3](#fig3){ref-type="fig"}B).Fig. 3A: Pharmacodynamic data---pooled analysis of platelet function tests. B: Pharmacodynamic data---pooled analysis of HRPR rates. SD, standard deviation; HRPR, high residual platelet reactivity; CI, confidence interval.Fig. 3

Sensitivity analysis suggested similar findings even after exclusion of the included RCT[@bib8] in terms of platelet function (SMD = 0.83, 95% CI = 0.38--1.27, *p* \< 0.001). Similarly for HRPR, exclusion of the RCT yielded similar results (odds ratio = 3.09, 95% CI = 1.90--5.02, *p* \< 0.001).

3.2. Pharmacokinetic effect {#sec3.2}
---------------------------

Two studies[@bib8], [@bib9] reported the effect of morphine on the pharmacokinetics of ticagrelor loading. Ticagrelor Cmax was significantly lower in the morphine group (MD = −481.84 ng/ml, 95% CI = −841.24 to −122.43 ng/ml, *p* = 0.009) ([Fig. 4](#fig4){ref-type="fig"}A). No heterogeneity was noted (I^2^ = 0%). Moreover, AUC of plasma concentration to time for ticagrelor was also significantly lower within the morphine group (SMD = −0.46, 95% CI = −0.84 to −0.08, *p* = 0.02) ([Fig. 4](#fig4){ref-type="fig"}B).Fig. 4A: Pharmacokinetic data---pooled analysis of Ticagrelor *C*~max~. B: Pharmacokinetic data---pooled analysis of ticagrelor concentration AUC. SD, standard deviation; CI, confidence interval; AUC, area under curve.Fig. 4

3.3. Clinical outcomes with morphine use {#sec3.3}
----------------------------------------

Three of the included studies[@bib3], [@bib8], [@bib13] noted a higher incidence of nausea/vomiting with morphine use with an OR of 5.39 (95% CI = 2.59--11.18, *p* \< 0.001) ([Fig. 5](#fig5){ref-type="fig"}A). There was no heterogeneity between studies (I^2^ = 0%). Exclusion of the RCT[@bib8] did not alter the findings significantly (OR = 5.39, 95% CI = 2.54--11.43, *p* \< 0.001).Fig. 5A: Pooled analysis of vomiting rates. B: Pooled analysis of MACE. CI, confidence interval; MACE, major adverse cardiovascular event.Fig. 5

In terms of in-hospital MACE, three studies reported a non-zero event rate of combined composite of re-infarction, stroke, and mortality. The meta-analysis showed no difference in in-hospital MACE between the morphine and non-morphine groups (OR = 0.90, 95% CI = 0.36--2.26, *p* = 0.83) ([Fig. 5](#fig5){ref-type="fig"}B). No heterogeneity was noted (I^2^ = 0%). The results were consistent even after exclusion of the RCT[@bib8] (OR = 0.79, 95% CI = 0.30--2.12, *p* = 0.64).

Funnel plots are noted in [Supplemental Fig. 2](#appsec1){ref-type="sec"}.

4. Discussion {#sec4}
=============

The salient findings of our analysis suggest (1) decreased platelet inhibition when morphine was administered prior to oral P2Y12 inhibitor use, (2) higher incidence of residual platelet reactivity with morphine use, (3) decreased levels of plasma ticagrelor if administered after morphine use, (4) increased incidence of nausea/vomiting with morphine use which may cause expulsion of oral agents including platelet inhibitors, and (5) no conclusion could be drawn regarding MACE because of low event rates and inadequacy of the analysis.

Our analysis suggests decreased platelet inhibition and consequently higher residual platelet reactivity with co-administration of morphine with P2Y12 inhibitors. No difference was noted in the prevalence of risk factors (age, hypertension, and diabetes) among both the groups ([Supplemental Fig. 1](#appsec1){ref-type="sec"}). However, the available data does not allow to draw conclusions regarding the effect on overall clinical outcome. This is mostly because of the small size of the included studies lacking sufficient power to detect a difference in hard outcomes. It underlines the lack of large-scale randomized studies to address this important question which could have important clinical implications.

Similar results were reported by the observational CRUSADE registry of high-risk ACS patients receiving clopidogrel.[@bib23] The authors reported a higher rates of adverse outcomes among patients receiving morphine (MI = 3.8% vs 3.0%, cardiogenic shock = 3.8% vs 2.3%, in-hospital death = 5.5% vs 4.7%, and composite of death or MI = 8.5% vs 7.1%). It is also possible that interaction between morphine and clopidogrel, with its requirement of 2-step metabolic activation, may be more significant. CRUSADE registry was excluded from our analysis because of lack of pharmacokinetic/dynamic data on platelet function.

Along with higher HRPR rates within the morphine group, Bellandi et al.[@bib13] noted lower incidence of ST segment resolution at 30 min in the morphine group (*p* = 0.047). The lowering of antiplatelet effect has also been noted in patients undergoing routine angiography and PCI and with the use of other narcotic analogs.[@bib21], [@bib24] In this study, higher HRPR rates were noted with fentanyl after 2 h (22% vs 3%, *p* = 0.02).

4.1. Solutions attempted {#sec4.1}
------------------------

Flierl et al.[@bib14] reported a prospective observational study of 50 prasugrel-treated STEMI patients who received morphine, with or without metoclopramide as an antiemetic. Among morphine treated patients, use of metoclopramide resulted in lower HRPR rates though this was not a significant finding. Siller-Matula et al.[@bib15] suggested the use of abciximab to counteract the delay in onset of antiplatelet effect.

There have been other attempts to counteract the adverse effect of morphine, while keeping the analgesic function intact. A prospective, randomized cross-over trial was presented in the American Heart Association meeting in 2016.[@bib25] The study aimed to assess the possible role of methylnaltrexone, a peripheral opioid receptor antagonist commonly used for opioid induced constipation, in preventing slow P2Y12 inhibition. This study (*n* = 30 patients) failed to show any benefit in plasma ticagrelor concentration with intravenous methylnaltrexone over placebo after morphine use in patients with coronary artery disease. A randomized study (Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients)[@bib26] is currently registered to further investigate this effect. Some other randomized studies are being performed to understand any possible role of naloxone (NCT02939248)[@bib27] and metoclopramide (NCT02939235)[@bib28] to alleviate this interaction.

4.2. Implications for clinical practice {#sec4.2}
---------------------------------------

In addition to advancing our understanding of morphine-P2Y12 interaction, our results could potentially influence current clinical practice. Until more data are available, judicious use of morphine with objective assessment of pain should be routinely practiced in a protocol-driven manner. As suggested in the European Society of Cardiology guidelines,[@bib6] delayed onset of antiplatelet effects afforded by morphine use could potentially result in early treatment failure.

Consideration of intravenous antiplatelet/anticoagulation agents for bridging the narcotic administered patients will also be helpful. A recent study[@bib15] suggested that co-administration of abciximab with P2Y12 inhibitors may counteract the increased platelet activity because of morphine loading. The CHAMPION PHOENIX trial[@bib29] suggested cangrelor as an effective intravenous antiplatelet agent during PCI. It will be interesting to assess the subset of patients who received narcotics for pain relief in this study cohort, and any beneficial effect cangrelor may have played as a bridge to oral antiplatelet agents. However, it has to be noted that the results of the present study do not show any increase in adverse events with morphine use.

4.3. Implications for research {#sec4.3}
------------------------------

Future studies should be designed to assess the dose--response, and the effect of time of administration of morphine on platelet activity. In addition, these studies should assess clinical outcomes such as stent thrombosis, target lesion revascularization, target vessel revascularization, myocardial infarction, and mortality. Non-morphine agents such as methylnaltrexone or metoclopramide can be studied to counter the gastrointestinal delay.[@bib14], [@bib26], [@bib28] The use of intravenous P2Y12 as a loading agent followed by oral P2Y12 or anticoagulants needs to be further explored.[@bib29] We also await the results of ongoing or recently concluded trials across the globe registered in the [clinicaltrials.gov](http://clinicaltrials.gov){#intref0015} website, as mentioned in [Table 4](#tbl5){ref-type="table"}.[@bib26], [@bib27], [@bib30], [@bib31], [@bib32], [@bib33]Table 4Ongoing studies, data obtained from clinicaltrials.gov. Last accessed 4/3/2018.Table 4Serial NumberTitleRecruitmentConditionsLocationsRegistration number1Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients[@bib26]RecruitingSTEMISwedenNCT029425502Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction[@bib31]RecruitingSTEMIChinaNCT029134693Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine[@bib27]RecruitingUnstable AnginaPolandNCT022178814Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine[@bib32]RecruitingUnstable AnginaPolandNCT022178825Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[@bib33]CompletedAMISwitzerlandNCT022178836Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention[@bib30]Not yet recruitingPCIUnited StatesNCT03476369[^3]

4.4. Limitations {#sec4.4}
----------------

Our analysis has several limitations. The analysis was largely based on non-randomized studies. The time difference from morphine use to oral P2Y12 inhibitor loading and the morphine dose was not known in most studies. The following confounders were not addressed appropriately: baseline pain scores or pain tolerance (more likely to request morphine), hypotension/shock (less likely to receive morphine), prior morphine use (more likely to request morphine), non-verbal/sedated patients (less likely to receive morphine), and variations in hospital or individual physician practice because of non-protocol driven use of morphine. A potential time-varying confounder was the residual pain score after the intervention which may have resulted in higher cumulative morphine dose administration and/or cross-over in some patients.

The platelet activity may also be affected by several factors leading to delay in absorption such as slow gastrointestinal transit in patients with gut ischemia, pretreatment hypotension/shock, improper technique of administration, and baseline gastrointestinal disturbances such as gastroparesis or vomiting, and this may be independent of morphine use. The effect of these factors on platelet activity can only be tested in a randomized controlled trial. In addition, there was lack of baseline platelet function testing prior to oral P2Y12 inhibitor loading to check for adequacy of platelet inhibition. Finally, pharmacokinetic data were only available for ticagrelor.

5. Conclusions {#sec5}
==============

Our meta-analysis suggests that co-administration of morphine with P2Y12 inhibitors decreases their efficacy in terms of inhibition of platelet activity. This did not translate into higher adverse clinical outcomes because of low event rates, inadequate for analysis. Our findings underline the need for an appropriately powered RCT to evaluate the clinical outcomes associated with narcotic-P2Y12 interaction.
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The following are the Supplementary data to this article:Supplemental Fig. 1A. Comparison of age, B: Comparison of hypertension and C: Comparison of diabetes.Supplemental Fig. 1Supplemental Fig. 2Funnel plots accompanying- A: Platelet function test analysis, B: HRPR rate analysis, C: Vomiting rate analysis and D: MACE rate analysis.Supplemental Fig. 2

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ihj.2019.03.003>.

[^1]: STEMI, ST-elevation myocardial infarction; AMI, acute myocardial infarction; VASP, vasodilator-associated stimulated phosphoprotein; ATLANTIC trial, Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation Myocardial Infarction to Open the Coronary Artery; ETAMI trial, Early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction; PRI, platelet reactivity index; PRU, platelet reactive units; AUC, area under curve; PCI, percutaneous coronary intervention; HRPR, high residual platelet reactivity.

[^2]: LAD, left anterior descending artery; LCx, left circumflex artery; RCA, right coronary artery; PCI, percutaneous coronary intervention; BMI, body mass index; HTN, hypertension; DM, diabetes; MI, myocardial infarction; CABG, coronary artery bypass grafting.

[^3]: STEMI: ST-elevation myocardial infarction, AMI: acute myocardial infarction, PCI: percutaneous coronary intervention.
